JP2010527331A - Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用 - Google Patents

Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用 Download PDF

Info

Publication number
JP2010527331A
JP2010527331A JP2010506698A JP2010506698A JP2010527331A JP 2010527331 A JP2010527331 A JP 2010527331A JP 2010506698 A JP2010506698 A JP 2010506698A JP 2010506698 A JP2010506698 A JP 2010506698A JP 2010527331 A JP2010527331 A JP 2010527331A
Authority
JP
Japan
Prior art keywords
aspirin
individual
modulator
adp receptor
sensitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527331A5 (enExample
Inventor
アール．プヒルリプス ダビド
アンドレ パトリクク
ジェイ．ホムクイ チャルレス
Original Assignee
ポルトラ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポルトラ ファーマシューティカルズ，インコーポレイテッド filed Critical ポルトラ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2010527331A publication Critical patent/JP2010527331A/ja
Publication of JP2010527331A5 publication Critical patent/JP2010527331A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010506698A 2007-05-03 2008-05-02 Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用 Pending JP2010527331A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91578407P 2007-05-03 2007-05-03
US91578507P 2007-05-03 2007-05-03
US94728907P 2007-06-29 2007-06-29
US94731607P 2007-06-29 2007-06-29
PCT/US2008/062565 WO2008137791A1 (en) 2007-05-03 2008-05-02 Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations

Publications (2)

Publication Number Publication Date
JP2010527331A true JP2010527331A (ja) 2010-08-12
JP2010527331A5 JP2010527331A5 (enExample) 2011-06-23

Family

ID=39943967

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010506698A Pending JP2010527331A (ja) 2007-05-03 2008-05-02 Ｔｐモジュレーターの、アスピリン感受性集団および他の集団における心血管障害の治療のための使用
JP2010506700A Pending JP2010526104A (ja) 2007-05-03 2008-05-02 トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010506700A Pending JP2010526104A (ja) 2007-05-03 2008-05-02 トロンボキサン受容体アンタゴニストを用いて血栓症を治療及び予防する単位用量製剤及び方法

Country Status (10)

Country Link
US (2) US20090012115A1 (enExample)
EP (2) EP2144999A4 (enExample)
JP (2) JP2010527331A (enExample)
KR (2) KR20100037029A (enExample)
CN (2) CN101711279A (enExample)
AU (2) AU2008247439A1 (enExample)
CA (2) CA2688319A1 (enExample)
IL (2) IL201885A0 (enExample)
MX (2) MX2009011745A (enExample)
WO (2) WO2008137793A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519281A (ja) * 2015-06-16 2018-07-19 ユニバーシティ・カレッジ・ダブリン，ナショナル・ユニバーシティ・オブ・アイルランド，ダブリン トロンボキサン受容体アンタゴニスト

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168137A1 (en) * 2006-12-20 2010-07-01 Johan Raud Combination for use in the treatment of inflammatory disorders
WO2008087371A1 (en) * 2007-01-16 2008-07-24 Cardoz Ab New combination for use in the treatment of inflammatory disorders
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
US10016417B2 (en) 2011-11-07 2018-07-10 Diakron Pharmaceuticals, Inc. Extended release formulation of a direct thrombin inhibitor
JP6183459B2 (ja) * 2012-08-06 2017-08-23 Jnc株式会社 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験
US12161632B2 (en) 2014-05-16 2024-12-10 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
JP6273072B2 (ja) * 2014-05-16 2018-01-31 カンバーランド ファーマシューティカルズ，インコーポレーテッド イフェトロバンにより心臓線維症を治療する組成物及び方法
KR102448406B1 (ko) * 2015-06-30 2022-09-27 큠버랜드 파마슈티컬즈 인코포레이티드 Ａｅｒｄ/천식에서 트롬복산 수용체 길항제
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
AU2021246444A1 (en) * 2020-03-31 2022-10-20 Martin Ogletree Methods and pharmaceutical compositions of thromboxane A2 receptor antagonist for the treatment of COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066008A2 (en) * 2004-12-14 2006-06-22 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895115A (en) * 1974-03-01 1975-07-15 Serono Ist Farm Method of inhibiting platelet aggregation
US5071866A (en) * 1989-07-31 1991-12-10 Bristol-Myers Squibb Company Arylpyrazole derivatives as anti-platelet agents
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
JP2005533830A (ja) * 2002-07-09 2005-11-10 ビー．エム．アール．エイ． コーポレイション ベスローテン フェンノートシャップ トロンボキサンａ２受容体アンタゴニストおよびｃｏｘ−２阻害剤の薬剤の組み合わせ
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066008A2 (en) * 2004-12-14 2006-06-22 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519281A (ja) * 2015-06-16 2018-07-19 ユニバーシティ・カレッジ・ダブリン，ナショナル・ユニバーシティ・オブ・アイルランド，ダブリン トロンボキサン受容体アンタゴニスト

Also Published As

Publication number Publication date
KR20100037029A (ko) 2010-04-08
MX2009011745A (es) 2010-02-12
CN101711279A (zh) 2010-05-19
IL201886A0 (en) 2010-06-16
CA2688317A1 (en) 2008-11-13
EP2146573A4 (en) 2012-11-21
US20090012115A1 (en) 2009-01-08
EP2144999A4 (en) 2010-06-16
AU2008247441A1 (en) 2008-11-13
JP2010526104A (ja) 2010-07-29
US20090012136A1 (en) 2009-01-08
CN101686668A (zh) 2010-03-31
KR20100032854A (ko) 2010-03-26
MX2009011744A (es) 2010-02-12
IL201885A0 (en) 2011-08-01
WO2008137793A1 (en) 2008-11-13
AU2008247439A1 (en) 2008-11-13
EP2144999A1 (en) 2010-01-20
WO2008137791A1 (en) 2008-11-13
CA2688319A1 (en) 2008-11-13
EP2146573A1 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
US20090012115A1 (en) Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
Cherpokova et al. Resolvin D4 attenuates the severity of pathological thrombosis in mice
Taraseviciene-Stewart et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension
US10206891B2 (en) Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent
Kang et al. A role for uric acid in the progression of renal disease
Mazaleuskaya et al. Druggable prostanoid pathway
Hannawi et al. Cardiovascular risk in rheumatoid arthritis: literature review
Lesault et al. Daily administration of the TP receptor antagonist terutroban improved endothelial function in high‐cardiovascular‐risk patients with atherosclerosis
Stitham et al. Prostacyclin, atherothrombosis and diabetes mellitus: physiologic and clinical considerations
JP2011515469A (ja) シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
Gurbel et al. Antiplatelet effect durability of a novel, 24-hour, extended-release prescription formulation of acetylsalicylic acid in patients with type 2 diabetes mellitus
Lorrain et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation
Kaur et al. Modulation of inflammatory changes in early stages of colon cancer through activation of PPARγ by diclofenac
EP1677779B1 (fr) Association d'un antagoniste des recepteurs tp et de clopidogrel
Bertagnolli Cox-2 and cancer chemoprevention: picking up the pieces
KR20110103428A (ko) 분비성 포스포리파제 Ａ２ （ｓＰＬＡ２） 억제제 또는 ｓＰＬＡ２ 억제제 조합 치료요법을 이용한 주요 유해 심장 사건 및 급성 관상동맥 증후군의 치료
CA3176619A1 (en) Methods and pharmaceutical compositions of thromboxane a2 receptor antagonist for the treatment of covid-19
Şahin et al. Analgesic nephropathy
Tang et al. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice
KR20040053884A (ko) 급성 관상동맥증후군 및 관련 상태의 치료를 위한항혈소판제와 병용하는 멜록시캄의 용도
Vural et al. Effects of ibuprofen on plasma endothelin levels and some vital parameters during endotoxin shock in rabbits
HK40085960A (en) Methods and pharmaceutical compositions of thromboxane a2 receptor antagonist for the treatment of covid-19
Sundy 3 Nonsteroidal Anti-Inflammatory Drugs in the Treatment
CA2734870A1 (en) Therapeutic agent for anca-related vasculitis
JP2004189711A (ja) 急性冠動脈症候群および関連病態の治療のための抗血小板薬と組合せたメロキシカムの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110428

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514